Cited by 579Click Chemistry and ApplicationsProtein Degradation and InhibitorsComputational Drug Discovery Methods

The DOI matches its Crossref record; 96 of the 97 references it cites were found in a registry or an index.

Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies

Bauer, Renato A.·2015·Drug Discovery Today

DOI 10.1016/j.drudis.2015.05.005

Open this paper in CoChat — free account

Abstract

Drugs that covalently bond to their biological targets have a long history in drug discovery. A look at drug approvals in recent years suggests that covalent drugs will continue to make impacts on human health for years to come. Although fraught with concerns about toxicity, the high potencies and prolonged effects achievable with covalent drugs may result in less-frequent drug dosing and in wide therapeutic margins for patients. Covalent inhibition can also dissociate drug pharmacodynamics (PD) from pharmacokinetics (PK), which can result in desired drug efficacy for inhibitors that have short systemic exposure. Evidence suggests that there is a reduced risk for the development of resistance against covalent drugs, which is a major challenge in areas such as oncology and infectious disease.

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2015.05.005

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Identifying and Characterizing Binding Sites and Assessing Druggability
Halgren, T. A. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800324m · Cited by 1,808
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. II. ROLE OF COVALENT BINDING IN VIVO
Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29664-1 · Cited by 1,203
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155
Acetaminophen-Induced Hepatic Necrosis
Jollow, D. J., Thorgeirsson, S. S., Potter, W. Z., Hashimoto, M., & Mitchell, J. R. (2008) · Pharmacology · doi:10.1159/000136547 · Cited by 1,091
The quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Janne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,076

Show all 97 references

Sorted by citations

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
He, H., Jiang, H., Chen, Y., Ye, J., Wang, A., Wang, C., Liu, Q., Liang, G., Deng, X., Jiang, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04947-6 · Cited by 827
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology
Gehringer, M., & Laufer, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 772
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
Douangamath, A., Fearon, D., Gehrtz, P., Krojer, T. J., Lukacik, P., Owen, C. D., Resnick, E., Strain-Damerell, C. M., Aimon, A., Ábrányi‐Balogh, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18709-w · Cited by 539
The Most Common Functional Groups in Bioactive Molecules and How Their Popularity Has Evolved over Time
Ertl, P., Altmann, E., & McKenna, J. M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00754 · Cited by 448
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
A Perspective on the Kinetics of Covalent and Irreversible Inhibition
Strelow, J. M. (2017) · SLAS Discovery · doi:10.1177/1087057116671509 · Cited by 392
Covalent inhibitors: a rational approach to drug discovery
Sutanto, F., Konstantinidou, M., & Dömling, A. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00154f · Cited by 389
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
Guo, Y., Liu, Y., Hu, N., Yu, D., Zhou, C., Shi, G., Zhang, B., Wei, M., Liu, J., Luo, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00687 · Cited by 376
Redox Signaling by Reactive Electrophiles and Oxidants
Parvez, S., Long, M. J. C., Poganik, J. R., & Aye, Y. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00698 · Cited by 372
Advances in covalent kinase inhibitors
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 337
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Resnick, E., Bradley, A., Gan, J., Douangamath, A., Krojer, T., Sethi, R., Geurink, P. P., Aimon, A., Amitai, G., Bellini, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02822 · Cited by 335
Covalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
Mortenson, D. E., Brighty, G. J., Plate, L., Bare, G. A. L., Chen, W., Li, S., Wang, H., Cravatt, B. F., Forli, S., Powers, E. T., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08366 · Cited by 303
Next generation 3D pharmacophore modeling
Schaller, D., Šribar, D., Noonan, T., Deng, L., Nguyen, T. N., Pach, S., Machalz, D., Bermúdez, M., & Wolber, G. (2020) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1468 · Cited by 297
Covalent Inhibition in Drug Discovery
Ghosh, A. K., Samanta, I., Mondal, A., & Liu, W. R. (2019) · ChemMedChem · doi:10.1002/cmdc.201900107 · Cited by 265
Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective
Pike, A., Williamson, B., Harlfinger, S., Martin, S. W., & McGinnity, D. F. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.013 · Cited by 250
Lysine‐Targeting Covalent Inhibitors
Pettinger, J., Jones, K., & Cheeseman, M. D. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707630 · Cited by 250
Mass Spectrometry-Based Protein Footprinting for Higher-Order Structure Analysis: Fundamentals and Applications
Liu, X. R., Zhang, M. M., & Gross, M. L. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00815 · Cited by 245
Mechanistic enzymology in drug discovery: a fresh perspective
Holdgate, G. A., Meek, T. D., & Grimley, R. L. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.219 · Cited by 227
Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics
Li, Q., Qu, C., Klauser, P. C., Li, M., Zheng, F. J., Wang, N., Li, X., Zhang, Q., Fu, X., Wang, Q., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.028 · Cited by 214
Bruton tyrosine kinase inhibitors for multiple sclerosis
Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00800-7 · Cited by 206
Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
Su, H., Yao, S., Zhao, W., Zhang, Y., Liu, J., Shao, Q., Wang, Q., Li, M., Xie, H., Shang, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23751-3 · Cited by 201
Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity
Lonsdale, R., Burgess, J., Colclough, N., Davies, N. L., Lenz, E. M., Orton, A. L., & Ward, R. A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00553 · Cited by 190
The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
Zhan, X., Li, Q., Xu, G., Xiao, X., & Bai, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1109938 · Cited by 203
Overview of Recent Strategic Advances in Medicinal Chemistry
Wu, G., Zhao, T., Kang, D., Zhang, J., Song, Y., Namasivayam, V., Kongsted, J., Pannecouque, C. C., Clercq, E. D., Poongavanam, V., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00359 · Cited by 184
Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities
O’Reilly, C., Doroudian, M., Mawhinney, L., & Donnelly, S. C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21385 · Cited by 182
Erratum: Mechanistic enzymology in drug discovery: a fresh perspective
Holdgate, G. A., Meek, T. D., & Grimley, R. L. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.257 · Cited by 182
The Symbiotic Relationship Between Drug Discovery and Organic Chemistry
Grygorenko, O. O., Volochnyuk, D. M., Ryabukhin, S. V., & Judd, D. B. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201903232 · Cited by 174
De Novo Design at the Edge of Chaos
Schneider, P., & Schneider, G. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01849 · Cited by 168
Systematic Study of the Glutathione (GSH) Reactivity ofN-Arylacrylamides: 1. Effects of Aryl Substitution
Cee, V. J., Volak, L. P., Chen, Y., Bartberger, M. D., Tegley, C. M., Arvedson, T., McCarter, J. D., Tasker, A. S., & Fotsch, C. H. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01018 · Cited by 165
The Taxonomy of Covalent Inhibitors
Tuley, A., & Fast, W. L. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00315 · Cited by 166
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 166
Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders
Cisar, J. S., Weber, O. D., Clapper, J. R., Blankman, J. L., Henry, C. L., Simon, G. M., Alexander, J. P., Jones, T. K., Ezekowitz, R. A. B., O’Neill, G. P., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00951 · Cited by 163
Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment
Liu, Y., Guo, Q., Yang, H., Zhang, X., Feng, N., Wang, J.-K., Liu, T., Zeng, K., & Tu, P. (2022) · ACS Central Science · doi:10.1021/acscentsci.2c00107 · Cited by 160
Kinetics and Thermodynamics of Reversible Thiol Additions to Mono- and Diactivated Michael Acceptors: Implications for the Design of Drugs That Bind Covalently to Cysteines
Krenske, E. H., Petter, R. C., & Houk, K. N. (2016) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6b02188 · Cited by 152
Comparative Evaluation of Covalent Docking Tools
Scarpino, A., Ferenczy, G. G., & Keserű, G. M. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00228 · Cited by 155
Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases
Zhang, X., Xu, A., Lv, J., Zhang, Q., Ran, Y., Wei, C., & Wu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111822 · Cited by 148
A Survey of the Role of Nitrile Groups in Protein–Ligand Interactions
Wang, Y. E., Du, Y., & Huang, N. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0252 · Cited by 149
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
Brighty, G. J., Botham, R. C., Li, S., Nelson, L. T., Mortenson, D. E., Li, G., Morisseau, C. H. P., Wang, H., Hammock, B. D., Sharpless, K. B., et al. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0530-4 · Cited by 148
Mechanism of inhibition of SARS-CoV-2 M pro by N3 peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity
Arafet, K., Serrano-Aparicio, N., Lodola, A., Mulholland, A. J., González, F. V., Świderek, K., & Moliner, V. (2020) · Chemical Science · doi:10.1039/d0sc06195f · Cited by 141
SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform
Hatcher, J. M., Wu, G., Zeng, C., Zhu, J., Fan, M., Patel, S. H., Wang, W., Ficarro, S. B., Leggett, A. L., Powell, C. E., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.01.013 · Cited by 135
A road map for prioritizing warheads for cysteine targeting covalent inhibitors
Ábrányi‐Balogh, P., Petri, L., Imre, T., Szijj, P. A., Scarpino, A., Hrast, M., Mitrović, A., Fonović, U. P., Németh, K., Barreteau, H., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.010 · Cited by 132
Glycomimetics for the inhibition and modulation of lectins
Leusmann, S., Ménová, P., Shanina, E., Titz, A., & Rademacher, C. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00954d · Cited by 139
Diacylfuroxans Are Masked Nitrile Oxides That Inhibit GPX4 Covalently
Eaton, J. K., Ruberto, R. A., Kramm, A., Viswanathan, V. S., & Schreiber, S. L. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10769 · Cited by 131
10 Years Into the Resurgence of Covalent Drugs
Vita, E. D. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0236 · Cited by 125
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4
Fairhurst, R. A., Knöpfel, T. F., Buschmann, N., Leblanc, C., Mah, R., Todorov, M., Nimsgern, P., Ripoche, S., Niklaus, M., Warin, N., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01019 · Cited by 121
Recent developments with rhodanine as a scaffold for drug discovery
Kaminskyy, D. V., Kryshchyshyn‐Dylevych, A., & Lesyk, R. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1388370 · Cited by 124
A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated with Kinetic Simulations
Mons, E., Roet, S., Kim, R. Q., & Mulder, M. P. C. (2022) · Current Protocols · doi:10.1002/cpz1.419 · Cited by 125
The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K
Mons, E., Jansen, I., Loboda, J., van Doodewaerd, B. R., Hermans, J., Verdoes, M., Boeckel, C. V. V., van Veelen, P. V., Turk, B., Turk, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11027 · Cited by 96
Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development
Huang, F., Han, X., Xiao, X., & Zhou, J. (2022) · Molecules · doi:10.3390/molecules27227728 · Cited by 134
Recent advances in the development of covalent inhibitors
Kim, H., Hwang, Y. S., Kim, M., & Park, S. B. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00068c · Cited by 114
Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication
Thenin-Houssier, S., de Vera, I. M. S., Pedró-Rosa, L., Brady, A., Richard, A. S., Konnick, B., Opp, S., Buffone, C., Fuhrmann, J., Kota, S., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02574-15 · Cited by 112
An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
Quan, B., Shuai, H., Xia, A., Hou, Y., Zeng, R., Liu, X., Lin, G., Qiao, J., Li, W.-P., Wang, F., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01119-7 · Cited by 114
New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design
Ray, S., & Murkin, A. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00293 · Cited by 108
Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)
Lu, Y., & Sun, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01248 · Cited by 104
Haste makes waste: A critical review of docking‐based virtual screening in drug repurposing for SARS‐CoV‐2 main protease (M‐pro) inhibition
Macip, G., Garcia‐Segura, P., Mestres‐Truyol, J., Saldivar‐Espinoza, B., Ojeda, M. J., Gimeno, A., Cereto‐Massagué, A., Garcı́a-Vallvé, S., & Pujadas, G. (2021) · Medicinal Research Reviews · doi:10.1002/med.21862 · Cited by 108
Recent Advances in Covalent Drug Discovery
Schaefer, D., & Cheng, X. (2023) · Pharmaceuticals · doi:10.3390/ph16050663 · Cited by 117
Advanced Activity-Based Protein Profiling Application Strategies for Drug Development
Wang, S., Tian, Y., Wang, M., Wang, M., Sun, G., & Sun, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00353 · Cited by 108
Strategies for targeting undruggable targets
Zhang, G., Zhang, J., Gao, Y., Li, Y., & Li, Y. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1969359 · Cited by 104
Covalent Small Molecules as Enabling Platforms for Drug Discovery
Dalton, S. E., & Campos, S. (2019) · ChemBioChem · doi:10.1002/cbic.201900674 · Cited by 101
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge
Picarazzi, F., Vicenti, I., Saladini, F., Zazzi, M., & Mori, M. (2020) · Molecules · doi:10.3390/molecules25235695 · Cited by 96
Beyond cysteine: recent developments in the area of targeted covalent inhibition
Mukherjee, H., & Grimster, N. P. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.011 · Cited by 95
Covalent targeting of acquired cysteines in cancer
Visscher, M., Arkin, M. R., & Dansen, T. B. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.11.004 · Cited by 95
Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond
Matthew, A. N., Leidner, F., Lockbaum, G. J., Henes, M., Zephyr, J., Hou, S., Rao, D. N., Timm, J., Rusere, L. N., Ragland, D. A., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00648 · Cited by 99
Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases
Schopfer, F. J., Vitturi, D. A., Jorkasky, D. K., & Freeman, B. Α. (2018) · Nitric Oxide · doi:10.1016/j.niox.2018.06.006 · Cited by 93
A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site Identification
Browne, C. M., Jiang, B., Ficarro, S. B., Doctor, Z. M., Johnson, J. L., Card, J. D., Sivakumaren, S. C., Alexander, W. M., Yaron, T. M., Murphy, C. J., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b07911 · Cited by 94
Modeling covalent-modifier drugs.
Awoonor-Williams, E., Walsh, A. G., & Rowley, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.05.009 · Cited by 90
Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?
Cianni, L., Feldmann, C., Gilberg, E., Gütschow, M., Juliano, L., Leitão, A., Bajorath, J., & Montanari, C. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00683 · Cited by 91
Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors
McAulay, K., Hoyt, E. A., Thomas, M. C., Schimpl, M., Bodnarchuk, M. S., Lewis, H. J., Barratt, D. G., Bhavsar, D., Robinson, D. M., Deery, M. J., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b13391 · Cited by 86
Strategic Design of Catalytic Lysine‐Targeting Reversible Covalent BCR‐ABL Inhibitors**
Quach, D., Tang, G., Anantharajan, J., Baburajendran, N., Poulsen, A., Wee, J. L. K., Retna, P., Li, R., Liu, B., Tee, D. H. Y., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202105383 · Cited by 84
Machine learning activation energies of chemical reactions
Lewis‐Atwell, T., Townsend, P. A., & Grayson, M. N. (2021) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1593 · Cited by 85
Privileged Electrophile Sensors: A Resource for Covalent Drug Development
Long, M. J. C., & Aye, Y. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.023 · Cited by 81
Drug-Target Residence Time Affects in Vivo Target Occupancy through Multiple Pathways
Lee, K. S. S., Yang, J., Niu, J., Ng, C., Wagner, K. M., Dong, H., Kodani, S. D., Wan, D., Morisseau, C. H. P., & Hammock, B. D. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00770 · Cited by 81
Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors
Cocco, M., Miglio, G., Giorgis, M., Garella, D., Marini, E., Costale, A., Regazzoni, L., Vistoli, G., Orioli, M., Massulaha‐Ahmed, R., et al. (2016) · ChemMedChem · doi:10.1002/cmdc.201600055 · Cited by 80
Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective
Aljoundi, A., Bjij, I., El-Rashedy, A. A. E., & Soliman, M. E. S. (2020) · The Protein Journal · doi:10.1007/s10930-020-09884-2 · Cited by 78
Inhibitors of the ATPase p97/VCP: From basic research to clinical applications
Kilgas, S., & Ramadan, K. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2022.12.007 · Cited by 82
Designing Irreversible Inhibitors—Worth the Effort?
González‐Bello, C. (2016) · ChemMedChem · doi:10.1002/cmdc.201500469 · Cited by 74
Systematic Study of the Glutathione Reactivity of N ‑Phenylacrylamides: 2. Effects of Acrylamide Substitution
Birkholz, A. B., Kopecky, D. J., Volak, L. P., Bartberger, M. D., Chen, Y., Tegley, C. M., Arvedson, T., McCarter, J. D., Fotsch, C. H., & Cee, V. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00749 · Cited by 73
Drugging K-RasG12C through covalent inhibitors: Mission possible?
Ni, D., Li, X., He, X., Zhang, H., Zhang, J., & Lu, S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.007 · Cited by 73
The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization
Thorarensen, A., Balbo, P., Banker, M. E., Czerwiński, R., Kühn, M., Maurer, T. S., Telliez, J., Vincent, F., & Wittwer, A. J. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115865 · Cited by 72
Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery
Hallenbeck, K. K., Turner, D., Renslo, A. R., & Arkin, M. R. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160719163839 · Cited by 73
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors
Milik, S. N., Lasheen, D. S., Serya, R. A. T., & Abouzid, K. A. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.023 · Cited by 71
Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors
Lin, H., Wang, M., Zhang, Y. W., Tong, S., Leal, R., Shetty, R. S., Vaddi, K., & Luengo, J. I. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00074 · Cited by 70
Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy
Baggio, C., Udompholkul, P., Gambini, L., Salem, A. F., Jossart, J. N., Perry, J. J. P., & Pellecchia, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01108 · Cited by 67
Applications of covalent chemistry in targeted protein degradation
Lu, D., Yu, X., Lin, H., Cheng, R., Monroy, E. Y., Qi, X., Wang, M. C., & Wang, J. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00362g · Cited by 69
Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants
(2022) · doi:10.1016/j.chempr.2022.07.012 · Cited by 64
Covalent inhibition of protein tyrosine phosphatases
Ruddraraju, K. V., & Zhang, Z. (2017) · Molecular BioSystems · doi:10.1039/c7mb00151g · Cited by 63
Electrophilic fatty acid nitroalkenes regulate Nrf2 and NF-κB signaling:A medicinal chemistry investigation of structure-function relationships
Khoo, N. K. H., Li, L., Salvatore, S. R., Schopfer, F. J., & Freeman, B. Α. (2018) · Scientific Reports · doi:10.1038/s41598-018-20460-8 · Cited by 68
Docking of Covalent Ligands: Challenges and Approaches
Sotriffer, C. (2018) · Molecular Informatics · doi:10.1002/minf.201800062 · Cited by 62
Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles
Bueno, A. B., Showalter, A. D., Wainscott, D. B., Stutsman, C., Marín, A., FICORILLI, J. V., Cabrera, O., Willard, F. S., & Sloop, K. W. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.696039 · Cited by 60
Kinetic Optimization of Lysine-Targeting Covalent Inhibitors of HSP72
Pettinger, J., Carter, M., Jones, K., & Cheeseman, M. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01709 · Cited by 59
Covalent peptides and proteins for therapeutics
Berdan, V. Y., Klauser, P. C., & Wang, L. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115896 · Cited by 59
Synthesis and Deployment of an Elusive Fluorovinyl Cation Equivalent: Access to Quaternary α-(1′-Fluoro)vinyl Amino Acids as Potential PLP Enzyme Inactivators
McCune, C. D., Beio, M. L., Sturdivant, J. M., de la Salud‐Bea, R., Darnell, B. M., & Berkowitz, D. B. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b04690 · Cited by 58
The Proteome‐Wide Potential for Reversible Covalency at Cysteine
Senkane, K., Vinogradova, E. V., Suciu, R. M., Crowley, V. M., Zaro, B. W., Bradshaw, J. M., Brameld, K. A., & Cravatt, B. F. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201905829 · Cited by 56
Costunolide improved dextran sulfate sodium-induced acute ulcerative colitis in mice through NF-κB, STAT1/3, and Akt signaling pathways
Xie, F., Zhang, H., Zheng, C., & Shen, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106567 · Cited by 57
How Reactive are Druggable Cysteines in Protein Kinases?
Awoonor‐Williams, E., & Rowley, C. N. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00454 · Cited by 57
Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine
Kharenko, O. A., Patel, R. G., Brown, S. D., Calosing, C., White, A., Damodharan, L., Suto, R. K., Duffy, B. C., Kitchen, D. B., McLure, K. G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00666 · Cited by 57
Drug design targeting active posttranslational modification protein isoforms
Meng, F., Liang, Z. T., Zhao, K., & Luo, C. (2020) · Medicinal Research Reviews · doi:10.1002/med.21774 · Cited by 56

Authors: Bauer, R. A.
Affiliations: Eli Lilly (United States) (US)
Corresponding author: Bauer, Renato A.
ORCID: Bauer, Renato A.
Venue: Drug Discovery Today
Publisher: Elsevier BV
Published: 2015-09
Volume: 20
Issue: 9
Pages: 1061-1073
ISSN: 1359-6446 (ISSN-L)
DOI: 10.1016/j.drudis.2015.05.005
OpenAlex: W248383993
Cited by: 534
References: 97
Citations by year: 2026: 36 · 2025: 43 · 2024: 46 · 2023: 56 · 2022: 57 · 2021: 70 · 2020: 57 · 2019: 51 · 2018: 47 · 2017: 33 · 2016: 29 · 2015: 8
FWCI: 1.90
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Drug Discovery Today (publishedVersion)
PubMed (publishedVersion)
Topics: Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords: covalent inhibitors, covalent drug design, history of drug discovery, drug toxicity, drug resistance, oncology therapeutics, infectious disease therapeutics, therapeutic window
MeSH terms: Drug Resistance, Pharmaceutical Preparations, Humans, Pharmacokinetics, Drug Design, Drug Approval, Drug Discovery, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks